

February 6, 2020

VIA SEDAR

British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
The Manitoba Securities Commission
Ontario Securities Commission
Autorité des marchés financiers
Nova Scotia Securities Commission
Financial and Consumer Services Commission (New Brunswick)
Office of the Superintendent of Securities (Prince Edward Island)
Office of the Superintendent of Securities Service Newfoundland and Labrador

Dear Sirs and Mesdames:

Re: Final Short Form Prospectus of Tetra Bio-Pharma Inc. (the "Issuer")

We refer you to the final short form prospectus (the "**Prospectus**") of the Issuer dated February 6, 2020 relating to the issuance of 29,245,300 Units of the Issuer.

We consent to being named in the introductory section of the Prospectus and under the heading "Interest of Experts" in the Prospectus, and consent to the use of our opinions set out under the heading "Eligibility for Investment" in the Prospectus, which opinions are provided as of the date of the Prospectus.

We have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that are (i) derived from our legal opinions provided in the Prospectus, or (ii) within our knowledge as a result of the services performed by us in connection with such opinions.

Yours truly,

(Signed) "Stikeman Elliott LLP"

Stikeman Elliott LLP